MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT)
Camilla Frimor, Casper Steenholdt, Ella Signe Kassandra Widigson, Jens Kjeldsen, Lone Larsen, Johan Burisch, Maiken Thyregod Joergensen, Morten Lee Halling, Charlotte Kloft, Mark Andrew Ainsworth · 2025
Read MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT) by Camilla Frimor, Casper Steenholdt, Ella Signe Kassandra Widigson, Jens Kjeldsen, Lone Larsen, Johan Burisch, Maiken Thyregod Joergensen, Morten Lee Halling, Charlotte Kloft, Mark Andrew Ainsworth (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742169.txt.
Description
Camilla Frimor and co-authors set out, in a 2025 protocol paper, the design of a Danish trial on precision dosing for bowel disease drugs. Two biologic drugs, vedolizumab and ustekinumab, treat Crohn's disease and ulcerative colitis well, but when symptoms stir, doctors often raise the dose on suspicion alone. The trial asks whether dosing steered by drug-level models can match that habit and save money.
The study will enroll 166 patients at six centers who have been stable on one of the drugs for at least three months. Half will keep symptom-based dosing; half will be dosed by blood measures fed into pharmacokinetic models with set targets. The main test is the share in steroid-free remission at the end. Healing of the gut lining, costs, and drug levels are also tracked.
Catalog record
| CREATOR | Camilla Frimor, Casper Steenholdt, Ella Signe Kassandra Widigson, Jens Kjeldsen, Lone Larsen, Johan Burisch, Maiken Thyregod Joergensen, Morten Lee Halling, Charlotte Kloft, Mark Andrew Ainsworth |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |